MAJIC: A RandoMised study of best Available therapy versus JAK Inhibition in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide

Trial Overview and Summary

MAJIC looks at a drug called ruxolitinib to treat high risk polycythaemia vera (PV) and essential thrombocythaemia (ET).

PV and ET are myeloproliferative disorders which cause the bone marrow to make too many blood cells.

Doctors usually treat these conditions with hydroxycarbamide. Unfortunately some people can’t take hydroxycarbamide or the disease stops responding to it so new treatments are needed.

Ruxolitinib stops signals that cancer cells use to divide and grow.

The aims of this trial are to find out

  • How well ruxolitinib works for people with PV and ET who can’t have hydroxycarbamide
  • How safe it is

Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator: Professor Claire Harrison  
Sponsor: University of Birmingham  
Funders: Bloodwise  
Disease Site: Myeloproliferative Neoplams  
Trial Type: Clinical Trial of an Investigational Medicinal Product  
Status: Open  
UKCRN Study ID: 11941  
Open to new sites? No  
Recruitment start date: 09-Aug-2012  
Anticipated Recruitment end date: 31-Jul-2016  
CRCTU Trial Management Team: Haematology  
Trial E-mail Address:  

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

Trial Documents [opens a new page]

More Information